[Study of the clinical and metabolic effects of an inhibitor of kaliuresis, amipromyzide (MK 870)].
D000293:Adolescent; D000328:Adult; D004232:Diuretics / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005198:Fanconi Syndrome / Q000188:drug therapy; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy; D006974:Hypertension, Malignant / Q000188:drug therapy*; D007008:Hypokalemia / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy; D013148:Spironolactone / Q000627:therapeutic use
D004232:Diuretics; D006146:Guanidines; D013148:Spironolactone; D004976:Ethacrynic Acid
Etude des effets cliniques et métaboliques d'un inhibiteur de la kaliurèse, l'amipromyzide (MK 870)